KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $77.6 million.

  • Amneal Pharmaceuticals' Change in Receivables rose 45582.71% to $77.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.8 million, marking a year-over-year increase of 14443.9%. This contributed to the annual value of $162.6 million for FY2024, which is 22878.16% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Change in Receivables stood at $77.6 million, which was up 45582.71% from $53.8 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Receivables registered a high of $150.8 million during Q2 2022, and its lowest value of -$196.0 million during Q1 2023.
  • For the 5-year period, Amneal Pharmaceuticals' Change in Receivables averaged around $13.2 million, with its median value being $28.6 million (2024).
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 27799.25% in 2021, then skyrocketed by 45582.71% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Change in Receivables stood at $34.5 million in 2021, then skyrocketed by 228.23% to $113.3 million in 2022, then tumbled by 168.18% to -$77.2 million in 2023, then soared by 137.04% to $28.6 million in 2024, then surged by 171.32% to $77.6 million in 2025.
  • Its Change in Receivables stands at $77.6 million for Q3 2025, versus $53.8 million for Q2 2025 and -$21.1 million for Q1 2025.